Business Context and Reporting Period
This Form 8-K is a current report filed by TRxADE HEALTH, INC. (trading symbol: MEDS) on January 30, 2023. The filing addresses a critical regulatory event regarding the company's continued listing on The Nasdaq Stock Market LLC. The registrant is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide specific financial statements, revenue figures, profit margins, cash flow data, or debt levels. The primary financial metric referenced is the minimum stockholders' equity requirement of $2,500,000 mandated by Nasdaq Listing Rule 5550(b), which the company failed to meet.
Material Changes and Events
- Delisting Determination: On January 30, 2023, the Nasdaq Listing Qualifications Staff notified the company that it failed to comply with the terms of a previously granted extension (originally set to expire January 25, 2023) to meet the minimum stockholders' equity requirement.
- Reason for Non-Compliance: The company did not complete its proposed transactions and failed to file the required Current Report Form 8-K by the January 25, 2023 deadline to evidence compliance.
- Immediate Consequence: Unless an appeal is requested, trading of the company's common stock is scheduled to be suspended at the opening of business on February 8, 2023, followed by the filing of a Form 25-NSE to remove the securities from Nasdaq listing.
Outlook, Management Commentary, and Risks
- Appeal Strategy: Management intends to submit a hearing request to the Nasdaq Hearings Panel. This request is expected to stay the delisting action pending the conclusion of the hearing process.
- Compliance Plan: At the hearing, the company plans to present a strategy to regain compliance with the minimum stockholders' equity requirement.
- Trading Status: Common stock will continue to trade on Nasdaq under the symbol "MEDS" at least until the hearing process concludes.
- Risks and Contingencies:
- There is no assurance that the company's plan will be accepted by the Panel or that compliance will be achieved.
- Delisting could result in a material decline in stock price, reduced liquidity, and difficulty in obtaining accurate quotations.
- Delisting may impair the company's ability to raise capital.
Investor Verification Checklist
- Verify the status of the appeal filed with the Nasdaq Hearings Panel and the scheduled hearing date.
- Confirm whether the company has successfully raised the required $2,500,000 in stockholders' equity to regain compliance.
- Monitor the stock trading status for any suspension notices effective February 8, 2023.
- Review the company's most recent Form 10-Q (filed November 7, 2022) and Form 10-K (filed March 28, 2022) for detailed risk factors and financial condition.